Mantle-cell lymphoma: Classification and therapeutic implications

Annals of Oncology

Volumn 7, Issue SUPPL. 6, 1996, Pages

  Fisher, R I ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

B cell lymphoma; Classification systems; MCL; Purine analogs; REAL classification; Working Formulation

Indexed keywords

ANTINEOPLASTIC AGENT; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PENTOSTATIN; PREDNISONE; PURINE DERIVATIVE; VINCRISTINE;

CANCER CLASSIFICATION; CANCER STAGING; CLINICAL FEATURE; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMANS; LYMPHOMA, SMALL CLEAVED-CELL, DIFFUSE; PURINES;

EID: 0030443128     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/7.suppl_6.S35     Document Type: Review

References (38)

1. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-35.
2. Berard CW, Dorfman RF. Histopathology of malignant lymphomas. Clin Haematol 1974; 3: 39-76.
3. Weisenburger DD, Nathwani BN, Diamond LW. Malignant lymphoma, intermediate lymphocytic type: A clinicopathologic study of 42 cases. Cancer 1981; 48: 1415-25.
4. Lennert K, Mohri N, Stein H. The histopathology of malignant lymphoma. Br J Haematol 1995; 31: 193-203.
5. Banks PM, Chan J, Cleary ML et al. Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992; 16: 637-40.
6. Harris NL, Jaffe ES, Stein H et al. A revised European-American Classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
7. Weisenburger DD, Kim H, Rappaport H. Mantle-zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma. Cancer 1982; 49: 1429-38.
8. Swerdlow SH, Habeshaw JA, Murray LJ et al. Centrocytic lymphoma: A distinct clinicopathologic and immunologic entity: A multiparameter study of 18 cases at diagnosis and relapse. Am J Pathol 1983; 113: 181-97.
9. Fisher RI, Dahlberg S, Nathwani BN et al. A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group Study. Blood 1995; 85: 1075-82.
10. Zucca E, Stein H, Coiffier B. European Lymphoma Task Force (ETLF): Report of the workshop on mantle cell lymphoma (MCL). Ann Oncol 1994; 5: 507-11.
11. Garcia-Conde J, Cabanillas F. Mantle cell lymphoma: A new lymphoproliferative entity with definite histopathological patterns, clinical characteristics and prognostic factors, and an investigational therapeutic approach. Ann Oncol 1995; 6: 305-6 (Letter).
12. Majilis A, Pugh W, Rodriguez MA, Cabanillas F. Three histological variants of mantle cell lymphoma (MCL) exhibit striking heterogeneity in clinical behavior and biological features. Blood 1993; 82: 388a (Abstr 1536).
13. Duggan MJ, Weisenburger DD, Ye YL et al. Mantle zone lymphoma: A clinicopathologic study of 22 cases. Cancer 1990; 66: 522-9.
14. Raffeld M, Jaffe ES. Bcl-1, t(11;14), and mantle cell lymphoma. Blood 1991; 78: 259-63.
15. Shivdasani RA, Hess JL, Skarin AT et al. Intermediate lymphocytic lymphoma: Clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 802-11.
16. Molot RJ, Meeker TC, Wittwer CT et al. Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas. Blood 1994; 83: 1626-31.
17. Weisenburger DD, Sanger WG, Armitage JO et al. Intermediate lymphocytic lymphoma: Immunophenotypic and cytogenetic findings. Blood 1987; 69: 1617-21.
18. Leroux D, Le Marc'hadour F, Gressin R et al. Non-Hodgkin's lymphomas with t(11;14)(q13;q32): A subset of mantle zone/ intermediate lymphocytic lymphoma? Br J Haematol 1991; 77: 346-53.
19. Vandenberghe E, de Wolf-Peeters C, van den Oord J et al. Translocation (11;14): A cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. J Pathol 1991; 163: 13-8.
20. Rosenberg C, Wong E, Petty E et al. Overexpression of PRAD1, a candidate BCL-1 breakpoint region oncogene, in centrocytic lymphomas. Proc Natl Acad Sci USA 1991; 88: 9638-42.
21. Yang WI, Zukerberg LR, Mokotura I et al. BCL-1 (Cyclin D1) protein expression in low grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994; 145: 86-96.
22. de Boer CJ, Schuuring E, Dreef E et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995; 86: 2715-23.
23. Wroblewski JM, Kilpatrick M, Faust J et al. Identification of nuclear and cytoplasmic forms of cyclin D1 using monoclonal antibodies. Blood 1993; 82: 117a.
24. Rimokh R, Berger F, Delsol G et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 1994; 83: 1871-5.
25. Dana BW, Dahlberg S, Nathwani BN et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmmunotherapy. J Clin Oncol 1993; 11: 644-51.
26. Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol 1995; 13: 2819-26.
27. Press OW, Grogan TM, Fisher RI. Evaluation and management of mantle cell lymphoma. Adv Leuk Lymph 1996; 6: 3-11.
28. Norton AJ, Matthews J, Pappa V et al. Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995; 6: 249-56.
29. Meusers P, Englehard M, Bartels H et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 1989; 7: 365-80.
30. Zucca E, Roggero E, Pinotti G et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257-62.
31. Narang S, Wolf BC, Neiman RS. Malignant lymphoma presenting with prominent splenomegaly: A clinicopathogic study with special reference to intermediate lymphoma. Cancer 1985; 55: 1948-57.
32. Pittaluga S, Wlodarska I, Stul MS et al. Mantle cell lymphoma: A clinicopathological study of 55 cases. Histopathology 1995; 26: 17-24.
33. Berger F, Felman P, Sonet A et al. Nonfollicular small B-cell lymphomas: A heterogeneous group of patients with distinct clinical features and outcome. Blood 1994; 83: 2829-935.
34. Coiffier B, Hiddemann W, Stein H. Mantle cell lymphoma: A therapeutic dilemma. Ann Oncol 1995; 6: 208-10 (Editorial).
35. Stewart DA, Vose JM, Weisenburger DD et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6: 263-6.
36. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94.
37. Bookman MA, Lardelli P, Jaffe ES et al. Lymphocytic lymphoma of intermediate differentiation: Morphologic, immunophenotypic, and prognostic factors. J Natl Cancer Inst 1990; 82: 742-7.
38. Anderson T, Bender RA, Fisher RI et al. Combination chemotherapy in non-Hodgkin's lymphoma: Results of long-term follow-up. Cancer Treat Rep 1977; 61: 1057-66.